000 03863nam a22004935i 4500
001 978-3-642-13663-4
003 DE-He213
005 20140220083744.0
007 cr nn 008mamaa
008 101029s2011 gw | s |||| 0|eng d
020 _a9783642136634
_9978-3-642-13663-4
024 7 _a10.1007/978-3-642-13663-4
_2doi
050 4 _aRC261-271
072 7 _aMJCL
_2bicssc
072 7 _aMED062000
_2bisacsh
082 0 4 _a614.5999
_223
100 1 _aRommel, Christian.
_eeditor.
245 1 0 _aPhosphoinositide 3-kinase in Health and Disease
_h[electronic resource] :
_bVolume 1 /
_cedited by Christian Rommel, Bart Vanhaesebroeck, Peter K. Vogt.
264 1 _aBerlin, Heidelberg :
_bSpringer Berlin Heidelberg :
_bImprint: Springer,
_c2011.
300 _aX, 310 p.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aCurrent Topics in Microbiology and Immunology,
_x0070-217X ;
_v346
505 0 _aPI3K – From the Bench to the Clinic and Back -- PI3K Book Introduction -- PDK1: The major transducer of PI 3-Kinase actions -- Protein Kinase B (PKB/Akt), a key mediator of the PI3K signaling pathway -- Regulatory subunits of class IA PI3K -- The Regulation of Class IA PI 3-kinases by Inter-Subunit Interactions -- Phosphoinositide signalling pathways in metabolic regulation -- Role of RAS in the regulation of PI 3-kinase -- More than just kinases: The scaffolding function of PI3K -- PI3K signalling in neutrophils -- PI 3-kinase p110beta regulation of platelet integrin alphaIIbbeta3 -- PI3Ks in lymphocyte signalling and development -- PI3 kinase regulation of skeletal muscle hypertrophy and atrophy -- Taking PI3Kdelta and PI3Kgamma one step ahead – Dual active PI3Kdelta/gamma inhibitors for the treatment of immune-mediated inflammatory diseases -- Oncogenic Mutations of PIK3CA in Human Cancers -- Structural Effects of Oncogenic PI3Kalpha Mutations -- Comparing the roles of the p110alpha and p110beta isoforms of PI3K in signaling and cancer -- Phosphatidylinositol 3-kinase (PI3K): The oncoprotein -- AKT Signaling in Physiology and Disease -- Faithfull modeling of PTEN loss driven diseases in the mouse -- PI3K as a target for therapy in haematological malignancies -- Clinical development of Phosphatidylinositol-3 kinase pathway inhibitors -- New inhibitors of the PI3K-Akt-mTOR pathway: Insights into mTOR signaling from a new generation of Tor kinase domain inhibitors (TORKinibs) -- Small molecule inhibitors of the PI3-kinase family -- Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance -- Subject index.
520 _aFrom humble beginnings over 25 years ago as a lipid kinase activity associated with certain oncoproteins, PI3K (phosphoinositide 3-kinase) has been catapulted to the forefront of drug development in cancer, immunity and thrombosis, with the first clinical trials of PI3K pathway inhibitors now in progress. Here the authors give a brief overview of some key discoveries in the PI3K area and their impact, and include thoughts on the current state of the field, and where it could go from here.
650 0 _aMedicine.
650 0 _aOncology.
650 0 _aHuman physiology.
650 1 4 _aBiomedicine.
650 2 4 _aCancer Research.
650 2 4 _aHuman Physiology.
650 2 4 _aMolecular Medicine.
700 1 _aVanhaesebroeck, Bart.
_eeditor.
700 1 _aVogt, Peter K.
_eeditor.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9783642136627
830 0 _aCurrent Topics in Microbiology and Immunology,
_x0070-217X ;
_v346
856 4 0 _uhttp://dx.doi.org/10.1007/978-3-642-13663-4
912 _aZDB-2-SBL
999 _c106908
_d106908